Skip to main content
. 2018 Sep 11;16(5):4283–4288. doi: 10.3892/etm.2018.6721

Figure 3.

Figure 3.

Effect of RvD1 on TNF-α, IL-1β and IL-6 expression. MG-63 cells were pretreated with different concentrations of RvD1 (50, 100, 200 nM) for 2 h, then these cells were treated with or without 1 µg/ml LPS for 48 h. The mRNA (A) and protein (B) levels of TNF-α, IL-1β and IL-6 were determined using RT-qPCR and western blot respectively. Control, Cells without any treatment; LPS, 1 µg/ml LPS treatment group; LPS + vehicle, 1 µg/ml LPS + 0.1% ethanol treatment group; LPS + RvD1 50, 1 µg/ml LPS + 50 nM RvD1 treatment group; LPS + RvD1 100, 1 µg/ml LPS + 100 nM RvD1 treatment group; LPS + RvD1 200, 1 µg/ml LPS + 200 nM RvD1 treatment group. **P<0.01 vs. Control; #P<0.05 vs. LPS; ##P<0.01 vs. LPS. RvD1, resolvin D1.